Tyme Technologies, INC.: management transactions · United States · SEC (Form 4)

About Tyme Technologies, INC.

TYME TECHNOLOGIES, INC. (ticker: TYME) is a US-listed company traded on the NASDAQ in the United States. For investors, it fits the profile of a small-cap biotech, historically focused on oncology and cancer-metabolism-based therapies. TYME Technologies was organized in Delaware and for much of its public-company history was headquartered in New York; more recent SEC materials identify a Bedminster, New Jersey business address. The company’s common stock has traded on the Nasdaq Capital Market since July 2017, reinforcing its place in the high-risk, growth-oriented segment of the US equity market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537917/000156459020026661/tyme-10k_20200331.htm?utm_source=openai)) Operationally, TYME described itself as an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs) intended to address a broad range of solid tumors and hematologic cancers. That makes the company fundamentally different from a commercial-stage pharmaceutical group: its value proposition has been tied primarily to preclinical and clinical development milestones, regulatory progress, and access to capital rather than recurring product revenue. In other words, the investment case has been driven by scientific optionality and binary event risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1556263/000119312522187527/d339682dex991.htm?utm_source=openai)) From a corporate-history perspective, TYME’s roots go back to a restructuring and reverse-merger era in the mid-2010s, with earlier corporate activity linked to the formation of the underlying entity in 2011 and later reorganization into the current public structure. This background matters for analysts because it highlights a company that has evolved through capital-market events and strategic repositioning rather than through a long history of scaled commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537917/000116169717000284/form_10-k.htm?utm_source=openai)) TYME’s competitive position has always been that of a niche oncology developer operating in a crowded field. Its therapeutic thesis centered on tumor-metabolism targeting and the possibility of relatively low-toxicity treatment options that could preserve patients’ quality of life. That differentiation is scientifically attractive, but in biotech investing it must be weighed against execution risk, clinical trial uncertainty, and ongoing financing needs. As a result, TYME has typically been viewed as a speculative small-cap name rather than a diversified healthcare platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1556263/000119312522187527/d339682dex991.htm?utm_source=openai)) Recent company news has suggested a strategic review posture rather than a straightforward operating-growth story. SEC-linked materials from 2022 indicate TYME initiated a formal process with Moelis & Company, signaling that management was evaluating strategic alternatives and potential value-maximizing transactions. For Form 4 insider-transaction readers, this is an important context point: insider activity in TYME should be interpreted against the backdrop of a company whose future has been closely tied to capital markets, strategic options, and the outcome of its oncology pipeline. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537917/000119312522087374/d282410dex991.htm?utm_source=openai))